BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 514 filers reported holding BIO-TECHNE CORP in Q2 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $765,924 | -26.2% | 11,252 | -11.5% | 0.02% | -14.8% |
| Q2 2023 | $1,038,007 | +8.3% | 12,716 | -1.5% | 0.03% | +3.8% |
| Q1 2023 | $958,238 | -11.2% | 12,916 | -0.8% | 0.03% | -13.3% |
| Q4 2022 | $1,078,766 | +12.4% | 13,016 | +285.1% | 0.03% | +3.4% |
| Q3 2022 | $960,000 | -18.1% | 3,380 | 0.0% | 0.03% | +3.6% |
| Q2 2022 | $1,172,000 | -19.9% | 3,380 | 0.0% | 0.03% | -3.4% |
| Q1 2022 | $1,464,000 | -16.3% | 3,380 | 0.0% | 0.03% | -9.4% |
| Q4 2021 | $1,749,000 | +6.8% | 3,380 | 0.0% | 0.03% | -5.9% |
| Q3 2021 | $1,638,000 | +1.7% | 3,380 | -5.5% | 0.03% | +3.0% |
| Q2 2021 | $1,610,000 | +12.6% | 3,575 | -4.5% | 0.03% | +6.5% |
| Q1 2021 | $1,430,000 | +23.6% | 3,744 | +2.7% | 0.03% | +19.2% |
| Q4 2020 | $1,157,000 | +24.7% | 3,644 | -2.7% | 0.03% | +18.2% |
| Q3 2020 | $928,000 | -8.7% | 3,744 | -2.7% | 0.02% | -15.4% |
| Q2 2020 | $1,016,000 | +35.6% | 3,849 | -2.5% | 0.03% | +23.8% |
| Q1 2020 | $749,000 | -13.6% | 3,949 | 0.0% | 0.02% | +10.5% |
| Q4 2019 | $867,000 | +3.7% | 3,949 | -7.6% | 0.02% | 0.0% |
| Q3 2019 | $836,000 | -12.6% | 4,272 | -6.9% | 0.02% | -13.6% |
| Q2 2019 | $957,000 | +4.5% | 4,590 | -0.5% | 0.02% | 0.0% |
| Q1 2019 | $916,000 | +37.1% | 4,614 | 0.0% | 0.02% | +22.2% |
| Q4 2018 | $668,000 | -29.1% | 4,614 | 0.0% | 0.02% | -18.2% |
| Q3 2018 | $942,000 | +35.2% | 4,614 | -2.1% | 0.02% | +29.4% |
| Q2 2018 | $697,000 | 0.0% | 4,714 | +2.2% | 0.02% | -5.6% |
| Q1 2018 | $697,000 | +16.6% | 4,614 | 0.0% | 0.02% | +20.0% |
| Q4 2017 | $598,000 | +3.6% | 4,614 | -3.4% | 0.02% | 0.0% |
| Q3 2017 | $577,000 | +4.9% | 4,777 | +2.1% | 0.02% | +7.1% |
| Q2 2017 | $550,000 | +13.2% | 4,677 | -2.1% | 0.01% | +7.7% |
| Q1 2017 | $486,000 | +1.9% | 4,777 | +3.0% | 0.01% | 0.0% |
| Q4 2016 | $477,000 | -3.4% | 4,637 | +2.9% | 0.01% | 0.0% |
| Q3 2016 | $494,000 | -2.8% | 4,507 | 0.0% | 0.01% | -7.1% |
| Q2 2016 | $508,000 | +7.2% | 4,507 | -10.1% | 0.01% | 0.0% |
| Q1 2016 | $474,000 | +8.0% | 5,013 | +2.8% | 0.01% | +7.7% |
| Q4 2015 | $439,000 | -7.4% | 4,875 | -4.9% | 0.01% | -18.8% |
| Q3 2015 | $474,000 | -8.0% | 5,126 | -1.9% | 0.02% | 0.0% |
| Q2 2015 | $515,000 | -1.7% | 5,226 | 0.0% | 0.02% | +6.7% |
| Q1 2015 | $524,000 | +8.5% | 5,226 | 0.0% | 0.02% | 0.0% |
| Q4 2014 | $483,000 | – | 5,226 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |